Pulmonary Hypertension Induced by Anticancer Drugs by Valentina, Mercurio et al.
133© Springer Nature Switzerland AG 2019 
A. Russo et al. (eds.), Cardiovascular Complications in Cancer Therapy, Current Clinical Pathology, 
https://doi.org/10.1007/978-3-319-93402-0_14
Pulmonary Hypertension Induced 
by Anticancer Drugs
Valentina Mercurio, Giulio Agnetti, 
Pasquale Pagliaro, and Carlo G. Tocchetti
 Introduction
Among the manifestations of anticancer drug- 
induced cardiotoxicity involving the pulmonary 
circulation, the development of pulmonary 
hypertension (PH) is a rare but well-recognized 
possible complication of childhood chemother-
apy and bone marrow transplantation (BMT) for 
leukemia [1], while other chemotherapeutic 
agents such as alkylating drugs (mitomycin C, 
cyclophosphamide) can determine progressive 
obstruction of small pulmonary veins rather than 
the distal pulmonary arterioles, thus leading to 
pulmonary veno-occlusive disease (PVOD) [2]. 
The tyrosine-kinase inhibitor (TKI) dasatinib, 
used as second-line treatment for chronic 
myelogenous leukemia, represents the most 
interesting example of a chemotherapeutic drug 
that can induce PH [3]. When the increase in 
 pulmonary pressure meets the hemodynamics 
criteria for precapillary PH (defined as mean 
 pulmonary artery pressure of >25  mmHg at 
rest, with pulmonary artery wedge pres-
sure ≤ 15 mmHg and pulmonary vascular resis-
tance >3 wood units in the absence of other 
causes of precapillary PH such as lung diseases, 
chronic thromboembolic PH, or other rare dis-
eases), this condition is diagnosed as drug- 
induced pulmonary arterial hypertension (PAH), 
and it is categorized in the group 1 of the clinical 
classification for PH [4] (Table 14.1).
PAH, regardless of the etiology, is a rare con-
dition that is often difficult to diagnose because 
of the nonspecific symptoms in the early stage of 
the disease but has a serious and progressive 
course, leading to the development of right heart 
failure and ultimately death [4, 5]. The latest 
guidelines for diagnosis and treatment of PH 
classified as likely the risk level of dasatinib to 
induce PAH, while possible the risk associated 
with some chemotherapeutic agents such as 
alkylating agents (mitomycin C, cyclophospha-
mide) [4]. Theoretically, PH with unclear or mul-
tiple causes may develop in patients with chronic 
myeloid leukemia per se, independently from 
chemotherapeutic drugs [6, 7]. However, data 
from the French PH Registry clearly showed that 
all incident cases of PH reported in chronic 
myeloid leukemia occurred only in patients 
V. Mercurio 
Division of Pulmonary and Critical Care Medicine, 
Johns Hopkins University School of Medicine, 
Baltimore, MD, USA 
G. Agnetti 
Department of Medicine, Johns Hopkins University 
School of Medicine, Baltimore, MD, USA 
DIBINEM, University of Bologna, Bologna, Italy 
P. Pagliaro 
Clinical and Biological Sciences, AOU San Luigi 
Gonzaga, Orbassano, Italy 
C. G. Tocchetti (*) 
Department of Translational Medical Sciences, 




treated with dasatinib. Furthermore, a direct link 
between dasatinib and PH was demonstrated by 
the clinical and hemodynamic improvement 
observed after switching dasatinib with another 
TKI, like nilotinib [3].
As mentioned, cyclophosphamide and other 
alkylating agents pulmonary vascular toxicity 
involves predominantly small venules, in the 
form of PVOD.  This condition represents the 
most severe form of pulmonary hypertension and 
unfortunately lacks effective pharmacological 
treatment so far. PVOD is a rare form of PH typi-
cally characterized by progressive obstruction of 
small pulmonary veins, due to a widespread 
fibrous intimal proliferation of veins and venules, 
often associated with pulmonary capillary dilata-
tion and proliferation [8]. Its diagnosis is quite a 
challenge, and it is often misclassified as idio-
pathic PAH. Chemotherapy-induced PVOD has a 
fatal course in most of the cases, even if few case 
reports suggest that specific treatment with the 
pulmonary vasodilator endothelin receptor antag-
onist may induce a favorable response [9, 10]. 
The pathophysiological mechanisms of PVOD 
are poorly understood. Limited case reports or 
case series of PVOD induced by polychemother-
apeutic treatment have been reported in the litera-
ture [10, 11]. Even if a clear relationship between 
a specific drug and PVOD is difficult to establish 
because of the use of several combinations of 
drugs in chemotherapeutic regimens, basing on 
observations from the literature, it has been dem-
onstrated that a key role in the development of 
this adverse toxicity is played by alkylating 
agents and in particular by mitomycin C and 
cyclophosphamide but also bleomycin and car-
mustine [2, 12–14]. Moreover, also BMT is con-
sidered a risk factor for PAH and PVOD [15, 16].
 Mechanisms of Pulmonary Vascular 
Damage Induced by Bone Marrow 
Transplantation
Concerning the effects of BMT on pulmonary cir-
culation, it has been known since 1984 a link 
between BMT and the development of PVOD, 
thus providing the earliest evidence that bone mar-
row compartment could adversely affect the pul-
monary vasculature [17]. The incidence of PAH in 
post-childhood cancer therapy and BMT is esti-
mated to be 1.6% based on single-center experi-
ence [1]. From a pathophysiological standpoint, it 
has been shown that bone marrow- derived cells 
contribute to the pathogenesis of pulmonary arte-
rial hypertension inducing remodeling and inflam-
mation [18]. Endothelial cell injury has been 
shown after allogenic BMT and has been directly 
linked to the development of several implications 
including graft-versus-host disease, PVOD, and 
endothelial leakage syndrome. Endothelial altera-
tions could occur also in the pulmonary circula-
tion, determining an imbalance in pulmonary 
vascular mediators, thus causing pulmonary vaso-
constriction and remodeling of the vascular struc-
ture [1]. Currently, deeper knowledge of the actual 
mechanisms that underlie the development of 
BMT-related PH is not available.
Table 14.1 Summary of the main antineoplastic treatments that can induce pulmonary vascular toxicity
Antineoplastic 
treatment Clinical feature Mechanism
Bone marrow 
transplantation
PAH, PVOD Endothelial dysfunction
Mitomycin C PVOD Endothelial dysfunction/VEGF receptor inhibition
Bleomycin PH secondary to 
pulmonary fibrosis
Oxidative damage, relative deficiency of the deactivating enzyme 
bleomycin hydrolase, genetic susceptibility, and production of 
inflammatory cytokines
Cyclophosphamide PVOD, rarely PAH Endothelial dysfunction
Dasatinib PAH Inhibition of tyrosine kinases implicated in cellular proliferation/
pulmonary vascular balance
Abbreviations: PAH Pulmonary Arterial Hypertension, PVOD Pulmonary Veno-Occlusive Disease, PH Pulmonary 
Hypertension, VEGF Vascular Endothelial Growth Factor
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 Mechanisms of Pulmonary Vascular 
Damage Induced by Mitomycin C 
and Bleomycin
Mitomycin C can induce PVOD. This condition 
is an uncommon form of PH typically character-
ized by the obstruction of small pulmonary veins 
and a poor prognosis. Patients with PVOD typi-
cally present with precapillary PH, peculiar tho-
racic high-resolution CT alterations, a low 
diffusing capacity of the lung for carbon monox-
ide, and severe hypoxemia. The estimated inci-
dence of PVOD in patients treated with 
mitomycin is 3.9 per 1000 per year, which is rel-
evantly higher in comparison to its incidence in 
the general population (0.5/million per year) 
[11]. Furthermore, females seemed to be more 
susceptible to mitomycin toxicity.
Several mechanisms have been described to 
concur in the development of mitomycin-induced 
PVOD.  This drug is an alkylating agent com-
monly used in several regimens for the treatment 
of different cancers [19]. The main mechanism of 
action of this drug implies its covalent binding to 
DNA determining DNA synthesis inhibition [20]. 
It results in decrease in cell viability and induces 
apoptosis in corneal endothelial cells [21]. Recent 
studies further demonstrated that mitomycin 
inhibits vascular endothelial growth factor 
(VEGF) expression [22], causing apoptosis resis-
tance and unlimited endothelial cell proliferation, 
similar to what happens in the sugen/hypoxic rat 
model [22]. In rats, intraperitoneal administration 
of mitomycin caused major remodeling of small 
pulmonary veins associated with foci of intense 
microvascular endothelial cell proliferation con-
sistent with PVOD [11]. These alterations were 
prevented by the administration of amifostine, a 
cytoprotective adjuvant used in chemotherapeu-
tic and radiotherapeutic regimens involving 
DNA-binding chemotherapeutic agents [11].
Bleomycin, another chemotherapeutic drug 
belonging to the class of the antibiotics and com-
monly used for the treatment of lymphomas, is 
also associated with the occurrence of PH [23]. 
The overall risk of pulmonary toxicity is about 
10%. Pulmonary hypertension due to bleomycin 
is secondary to the development of pulmonary 
fibrosis. The underlying mechanism is mainly 
related to oxidative damage, relative deficiency 
of the deactivating enzyme bleomycin hydrolase, 
genetic susceptibility, and production of inflam-
matory cytokines [24].
 Mechanisms of Pulmonary Vascular 
Damage Induced by Alkylating 
Agents
Alkylating agents may be responsible of the devel-
opment of PVOD rather than PAH, and this form 
of toxicity has been known for several years [12].
Cyclophosphamide, an alkylating agent, is 
used as immunosuppressant in several autoim-
mune diseases and as a common component of 
multidrug regimens for treatment of hematologi-
cal and solid cancers. In different animal models, 
cyclophosphamide demonstrated to be able to 
induce PH. From a histopathological standpoint, 
all these models revealed significant alterations 
of the pulmonary venules and veins, highly sug-
gestive of PVOD [2]. Specifically, cyclophospha-
mide induced pulmonary vein wall thickening 
due to adventitial and transmural inflammatory 
infiltration and fibrosis, muscularization of distal 
microvessels with foci of pulmonary congestion, 
consistent with PVOD [2]. It has been demon-
strated that endothelial cells are more susceptible 
to the effector of cyclophosphamide than other 
cell types [25, 26].
 Mechanisms of Pulmonary Vascular 
Damage Induced by Dasatinib
The actual incidence of PAH during treatment 
with dasatinib is still a matter of debate, ranging 
from 0.6% up to 11% [3].
From a clinical standpoint, median delay for 
dasatinib-induced PAH diagnosis is usually 
34  months (ranging from 8 to 40  months after 
exposure to the drug). Unlike other forms of 
PAH, dasatinib-induced PAH is often reversible 
after drug discontinuation or replacement with 
another TKI, such as nilotinib [3, 27–30]. In 
some cases, because of the persistence of 
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 symptoms and of the increase in pulmonary arte-
rial pressures, specific treatment with pulmonary 
vasodilator agents has been prescribed, with ben-
eficial results [3, 27–30].
Dasatinib, as already mentioned above, is an 
oral second-generation TKI recently approved as 
a first- or second-line treatment for chronic 
Philadelphia chromosome-positive (which corre-
sponds to the reciprocal translocation between 
chromosome 9 and 22, thus causing the Abelson 
TK gene, ABL, to fuse with the breakpoint  cluster 
region of the BRC gene) myelogenous leukemia 
[31, 32] and currently approved also for second-
line treatment of Philadelphia chromosome- 
positive acute lymphoblastic leukemia [33]. The 
BCR/ABL oncogene is responsible for a patho-
genic tyrosine kinase signal transduction protein 
that triggers intracellular signaling, activating 
multiple transduction cascades. This pathway 
promotes growth, proliferation, and survival of 
hematopoietic cells [34] and plays a role in defec-
tive DNA repair, alteration of cellular adhesion, 
and inhibition of apoptosis [35]. Deregulated 
BCR/ABL tyrosine kinase activity is the molecu-
lar marker for chronic myelogenous leukemia. 
Drugs like imatinib, nilotinib, and dasatinib that 
target BCR/ABL tyrosine kinase and block its 
activity lead to the induction of apoptosis and 
inhibits malignant cells’ proliferation [36]. 
Dasatinib, characterized by a 300-fold higher 
affinity for BRC/ABL kinase in comparison with 
imatinib, is more effective in patients who failed 
treatment with imatinib [37]. However, dasatinib 
is also able to inhibit several other kinases, 
including the Src, a family of receptors that play 
a crucial role in smooth muscle cell proliferation 
and vasoconstriction. Therefore, is has been 
hypothesized that this drug could alter the prolif-
eration/antiproliferation balance in endothelial 
and pulmonary arterial smooth muscle cells, thus 
determining adverse remodeling of pulmonary 
arterioles and then PAH [38, 39].
Several receptor tyrosine kinases, such as 
platelet-derived growth factor (PDGF) receptor 
beta and VEGF receptor 2, are implicated in the 
pathophysiology of PAH.  In particular, PDGF 
signaling pathway mediates endothelial cell dys-
function and proliferation and migration of vas-
cular smooth muscular cells [40–42]. It has been 
demonstrated that, beside perturbation of the bal-
ance between vasoconstriction and vasodilation, 
PDGF ligands and receptors are increased in 
idiopathic PAH. In addition, PDGF was shown to 
primarily contribute in vascular smooth muscle 
cell proliferation and hyperplasia in PAH [43, 
44]. Interestingly, another TKI inhibitor,  imatinib, 
has been shown to have anti- vasoproliferative 
properties and to be effective in improving hemo-
dynamics in both animal models and in a ran-
domized controlled clinical trial [44, 45]. 
Nevertheless, the use of imatinib for treatment of 
PAH has been discouraged because of severe 
adverse events, relevant side effects, and high 
discontinuation rate during the open-label exten-
sion phase study [46].
Mechanistically, imatinib reversed the overex-
pression and increased phosphorylation of PDGF 
receptor beta that is present also in pulmonary 
arteries from animal models of PH, inhibited 
PDGF receptor-related ERK1/2 activation in 
lungs of these animals thereby suppressing pul-
monary artery smooth muscle cell proliferation 
and inducing cellular apoptosis [44]. While sig-
nificantly lower concentrations of dasatinib are 
needed to obtain BCR/ABL inhibition in com-
parison to imatinib, the effect of dasatinib on 
c-kit and PDGF receptor are rather similar. In 
addition, and differently from imatinib, dasatinib 
also inhibits the SRC family of kinases [47]. The 
large spectrum of inhibition of dasatinib led to 
hypothesize that by inhibiting Src, a family of 
receptors that play a crucial role in smooth mus-
cle cell proliferation and vasoconstriction, this 
drug could alter the proliferation/antiprolifera-
tion balance in endothelial and pulmonary arte-
rial smooth muscle cells besides its inhibition of 
PDGF receptor (that instead determines an 
improvement of pulmonary vascular disease) 
[38]. Whether this aspect of the compound is 
causally related to PAH development is still 
poorly understood.
The extreme differences in terms of effects on 
pulmonary circulation between imatinib and 
dasatinib suggest that dasatinib-induced pulmo-
nary vascular toxicity is molecule-related rather 
than class-related. On the other side, in vivo and 
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in vitro studies aimed at evaluating the effects of 
dasatinib and imatinib on pulmonary vasculature 
demonstrated that both TKI increased levels of 
nitric oxide, a potent vasodilator, without induc-
ing PAH-related adverse remodeling, thus sug-
gesting that both the drugs could promote 
beneficial effects for PAH [48]. These results are 
in contrast with the clinical evidence of dasatinib- 
induced PAH.  In conclusion, there is still poor 
knowledge about the actual mechanisms underly-
ing the damage of pulmonary vessels induced by 
dasatinib.
 Screening and Clinical Management 
of Anticancer Drug-Induced 
Pulmonary Hypertension
Before initiation of antineoplastic drugs that have 
a known possible risk of causing PAH, baseline 
evaluation for signs and symptoms of underlying 
cardiopulmonary disease is mandatory. 
Echocardiographic assessment, including the 
search for signs of right ventricular overload, 
should be considered [49]. Transthoracic echo-
cardiography is used to explore the effects of 
increase in pulmonary pressure on the heart, 
especially on the right ventricle, and to estimate 
pulmonary arterial systolic pressure from con-
tinuous wave Doppler measurements of the tri-
cuspid regurgitation [50]. This evaluation before 
chemotherapy initiation may help in interpreta-
tion of follow-up echocardiographic examina-
tions in patients reporting symptoms potentially 
correlated with the development of PAH, like 
exercise limitation or exertional dyspnea during 
treatment. Noninvasive cardiovascular surveil-
lance should be considered in all patients during 
treatment with cancer drugs known to cause PAH 
or pulmonary vascular damage, particularly in 
case of the appearance of new symptoms like 
exertional dyspnea, fatigue, or angina.
The recently published position paper of the 
Task Force for cancer treatments and cardiovas-
cular toxicity of the European Society of 
Cardiology suggests to consider echocardio-
graphic evaluation every 3 to 6 months in asymp-
tomatic patients. It is unclear whether patients 
with baseline signs of right ventricular overload 
due to comorbidities commonly associated with 
elevated pulmonary arterial pressure (e.g., 
chronic obstructive pulmonary disease, left heart 
dysfunction) are at higher risk of chemotherapy- 
induced PAH and require more frequent surveil-
lance with echocardiography. When drug-induced 
PAH is suspected, referral to a specialized pul-
monary hypertension team is recommended to 
assess indications for right heart catheterization 
[4]. Multidisciplinary team discussions should be 
held among Cardiologists, Oncologists and 
Hematologists regarding the risk–benefit ratio of 
continuing cancer treatment with PAH drug ther-
apy vs. stopping or replacing the culprit drug [4]. 
Chemotherapy-induced PAH is often reversible 
with drug cessation (e.g., in the case of dasat-
inib), although usually without restoration of 
normal right heart hemodynamics [3]. Targeted 
therapy for PAH may be useful temporarily or 
permanently.
 Remarks and Conclusion
PH remains a rare complication of antineoplastic 
drugs, suggesting possible individual susceptibil-
ity, and further studies are needed to better under-
stand the underlying mechanisms, to identify 
patients at risk of developing pulmonary vascular 
toxicity and how to manage and treat this 
condition.
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